Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21267 | 0.75 | — | — | |
| SCHEMBL1374665 | 0.75 | — | — | |
| SCHEMBL20477815 | 0.73 | TSHR (0.38) | TSHRHTR2CCES1 | |
| SCHEMBL327799 | 0.69 | TSHR (0.43) | TSHRHTR2CCES1 | |
| SCHEMBL31251596 | 0.69 | TSHR (0.43) | TSHRHTR2CCES1 | |
| SCHEMBL8912020 | 0.69 | TSHR (0.43) | TSHRHTR2CCES1 | |
| SCHEMBL11095966 | 0.69 | TSHR (0.43) | TSHRHTR2CCES1 | |
| SCHEMBL1751341 | 0.69 | TSHR (0.43) | TSHRHTR2CCES1 | |
| SCHEMBL3884 | 0.67 | TSHR (0.48) | TSHRHTR2C | |
| SCHEMBL286696 | 0.67 | TSHR (0.48) | TSHRHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11999892-B2 | Liquid crystal composition, liquid crystal display element and compound | DIC CORPORATION (JP) | 2024-06-04 | — | — | US | claimed |
| CN-112662404-B | Liquid crystal composition, liquid crystal display element, and polymerizable compound | DIC株式会社 | 2024-05-03 | — | — | CN | claimed |
| US-20230131540-A1 | LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTAL DISPLAY ELEMENT AND COMPOUND | DIC CORPORATION (JP) | 2023-04-27 | — | — | US | claimed |
| CN-113698298-A | Polymerizable compound and liquid crystal composition using same | DIC株式会社 | 2021-11-26 | — | — | CN | claimed |
| CN-113493694-A | Compound, liquid crystal composition and liquid crystal display element | DIC株式会社 | 2021-10-12 | — | — | CN | claimed |
| CN-113174269-A | Polymerizable compound-containing liquid crystal composition and liquid crystal display element using same | DIC株式会社 | 2021-07-27 | — | — | CN | claimed |
| CN-113025345-A | Liquid crystal composition containing polymerizable compound and liquid crystal display element | DIC株式会社 | 2021-06-25 | — | — | CN | claimed |
| CN-112789344-A | Polymerizable compound-containing liquid crystal composition, liquid crystal display element, and polymerizable compound | DIC株式会社 | 2021-05-11 | — | — | CN | claimed |
| CN-112662404-A | Liquid crystal composition, liquid crystal display element, and polymerizable compound | DIC株式会社 | 2021-04-16 | — | — | CN | claimed |
| CN-112080290-A | Liquid crystal composition containing polymerizable compound and liquid crystal display element | DIC株式会社 | 2020-12-15 | — | — | CN | claimed |
| EP-2975023-B1 | GUANIDINOBENZOIC ACID ESTER COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2018-05-30 | — | — | EP | claimed |
| US-9969709-B2 | Guanidinobenzoic acid ester compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-15 | — | — | US | claimed |
| US-9828548-B2 | Liquid-crystal composition | DIC CORPORATION (JP) | 2017-11-28 | — | — | US | claimed |
| US-20160031847-A1 | GUANIDINOBENZOIC ACID ESTER COMPOUND | ASTELLAS PHARMA INC. (JP) | 2016-02-04 | — | — | US | claimed |
| EP-2975023-A1 | GUANIDINOBENZOIC ACID ESTER COMPOUND | Astellas Pharma Inc. (JP) | 2016-01-20 | — | — | EP | claimed |
| US-20150259600-A1 | LIQUID-CRYSTAL COMPOSITION | DIC CORPORATION (JP) | 2015-09-17 | — | — | US | claimed |
| EP-2860236-A1 | LIQUID-CRYSTAL COMPOSITION | DIC Corporation (JP) | 2015-04-15 | — | — | EP | claimed |
| US-20140327862-A1 | FERROELECTRIC LIQUID CRYSTAL COMPOSITION AND FERROELECTRIC LIQUID CRYSTAL DISPLAY DEVICE | DIC CORPORATION (JP) | 2014-11-06 | — | — | US | claimed |
| EP-2423182-A1 | DIACYLETHYLENEDIAMINE COMPOUND | Astellas Pharma Inc. (JP) | 2012-02-29 | — | — | EP | claimed |
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-02-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031847-A1 | GUANIDINOBENZOIC ACID ESTER COMPOUND | SERPINB1, REN, SPINT2 | TSHR 1073/4885HTR2C 3564/4885CES1 355/4885 |
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | DGAT1, DGAT2, DIMT1 | TSHR 4189/4885HTR2C 2559/4885CES1 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.